CytoSorbents, Inc
CytoSorbents is dedicated to expanding the dimensions of blood purification through innovative bead technology. Their mission is to help restore balance in the blood, protect organs, and save lives by removing harmful substances that other therapies cannot efficiently eliminate. They focus on critical care, cardiovascular, liver, kidney, and pet health applications, providing advanced solutions like CytoSorb, PuriFi, ECOS, VetResQ, and HemoDefend-BGA. With a global presence in over 75 countries, CytoSorbents emphasizes personalized, targeted treatment in critical health challenges, supported by extensive research, clinical evidence, and strategic partnerships.
Industries
Nr. of Employees
medium (51-250)
CytoSorbents, Inc
One Gateway Center, Suite 2600, Newark, NJ 07102, USA
Patents
Crosslinked polysaccharide based absorbents for removal of anti-A and/or anti-B antibodies from human plasma and whole blood
US-12121879-B2
View DetailsUse of a hemocompatible porous polymer bead sorbent for removal of endotoxemia-inducing molecules
US-11826724-B2
View DetailsMulti-functional hemocompatible porous polymer bead sorbent for removing protein based toxins and potassium from biological fluids
US-11723916-B2
View Details
Crosslinked polysaccharide based absorbents for removal of anti-A and/or anti-B antibodies from human plasma and whole blood
US-12121879-B2
View DetailsUse of a hemocompatible porous polymer bead sorbent for removal of endotoxemia-inducing molecules
US-11826724-B2
View DetailsMulti-functional hemocompatible porous polymer bead sorbent for removing protein based toxins and potassium from biological fluids
US-11723916-B2
View DetailsProducts
Sterile single‑use whole‑blood adsorber cartridge
Sterile, single‑use extracorporeal adsorber cartridge containing porous polymer beads for selective removal of elevated hydrophobic substances from whole blood; designed for integration into extracorporeal circuits.
Standalone hemoperfusion platform
Independent hemoperfusion platform capable of driving blood through adsorption cartridges for standalone hemoperfusion treatments without reliance on a primary dialysis or bypass machine.
Ex‑vivo perfusion adsorption module
Sterile adsorption cartridge configured for inclusion in organ perfusion circuits to reduce inflammatory mediators in perfusate during normothermic or hypothermic machine perfusion.
Veterinary emergency hemoadsorption device
Adsorption cartridge adapted for veterinary emergency hemoadsorption use to remove harmful substances from animal blood during critical illness.
Preclinical plasma antibody‑removal filter
Prototype adsorption filter developed to selectively remove anti‑A and anti‑B antibodies from plasma to enable production of low‑titer universal plasma; currently at preclinical stage.
Investigational drug-adsorption cartridges
Adsorber cartridges under clinical investigation for targeted drug removal or novel therapeutic indications; regulatory status and availability vary by jurisdiction.
Sterile single‑use whole‑blood adsorber cartridge
Sterile, single‑use extracorporeal adsorber cartridge containing porous polymer beads for selective removal of elevated hydrophobic substances from whole blood; designed for integration into extracorporeal circuits.
Standalone hemoperfusion platform
Independent hemoperfusion platform capable of driving blood through adsorption cartridges for standalone hemoperfusion treatments without reliance on a primary dialysis or bypass machine.
Ex‑vivo perfusion adsorption module
Sterile adsorption cartridge configured for inclusion in organ perfusion circuits to reduce inflammatory mediators in perfusate during normothermic or hypothermic machine perfusion.
Veterinary emergency hemoadsorption device
Adsorption cartridge adapted for veterinary emergency hemoadsorption use to remove harmful substances from animal blood during critical illness.
Preclinical plasma antibody‑removal filter
Prototype adsorption filter developed to selectively remove anti‑A and anti‑B antibodies from plasma to enable production of low‑titer universal plasma; currently at preclinical stage.
Investigational drug-adsorption cartridges
Adsorber cartridges under clinical investigation for targeted drug removal or novel therapeutic indications; regulatory status and availability vary by jurisdiction.
Services
Onboarding, clinician training, procedural guidance and therapy monitoring resources for integration of adsorber cartridges into extracorporeal circuits; includes anticoagulation and cartridge-exchange recommendations.
Collaborative study design, registry participation support, data consolidation and publication assistance for randomized trials, observational studies and meta-analyses.
Development of patient selection criteria, timing and dosing protocols (including recommendations for early intervention and cartridge exchange) and morbidity-focused endpoints to tailor hemoadsorption therapy.
Technical and commercial collaboration to certify compatibility with third-party blood purification and critical-care platforms, provide adapter kits, and enable joint go-to-market activities.
In-house and partnered R&D for new adsorption applications, prototype testing, and progression to clinical trials including plasma antibody-removal concepts.
Onboarding, clinician training, procedural guidance and therapy monitoring resources for integration of adsorber cartridges into extracorporeal circuits; includes anticoagulation and cartridge-exchange recommendations.
Collaborative study design, registry participation support, data consolidation and publication assistance for randomized trials, observational studies and meta-analyses.
Development of patient selection criteria, timing and dosing protocols (including recommendations for early intervention and cartridge exchange) and morbidity-focused endpoints to tailor hemoadsorption therapy.
Technical and commercial collaboration to certify compatibility with third-party blood purification and critical-care platforms, provide adapter kits, and enable joint go-to-market activities.
In-house and partnered R&D for new adsorption applications, prototype testing, and progression to clinical trials including plasma antibody-removal concepts.
Expertise Areas
- Hemoadsorption blood purification
- Critical care extracorporeal therapies (CRRT/ECMO/CPB integration)
- Endothelial protection and fluid-balance management in septic shock
- Perioperative antithrombotic drug removal during cardiac surgery
Key Technologies
- Porous polymer bead adsorbents
- Hemoadsorption / whole-blood adsorption
- Cytokine and biomarker adsorption (TNF-α, IL-6, IL-1β, PCT)
- Myoglobin adsorption for rhabdomyolysis
News & Updates
A major event in Copenhagen, Denmark, from October 8-11, 2025, focusing on cardiovascular and critical care innovations.
A critical care conference in Munich, Germany, from October 25-29, 2025, showcasing latest advancements in intensive care.
A recent meta-analysis highlights the effectiveness of CytoSorb hemoadsorption in septic shock patients, emphasizing early and high-intensity treatment.
A large study reviewing outcomes in septic shock patients treated with CytoSorb, showing improved survival with early and high-dose therapy.
CytoSorbents' literature database surpasses 1,000 peer-reviewed publications, making it the most researched hemoadsorption therapy of its kind.
A major event in Copenhagen, Denmark, from October 8-11, 2025, focusing on cardiovascular and critical care innovations.
A critical care conference in Munich, Germany, from October 25-29, 2025, showcasing latest advancements in intensive care.
A recent meta-analysis highlights the effectiveness of CytoSorb hemoadsorption in septic shock patients, emphasizing early and high-intensity treatment.
A large study reviewing outcomes in septic shock patients treated with CytoSorb, showing improved survival with early and high-dose therapy.
CytoSorbents' literature database surpasses 1,000 peer-reviewed publications, making it the most researched hemoadsorption therapy of its kind.